References
- Asmussen Frank V, Bjerge B, Houborg E. Shifts in substitution treatment policy in Denmark from 2000–2011. Substance Use & Misuse 2013; 48: 997–1009
- Babor T, Caulkins J, Edwards G, Fischer B, Foxcroft D, Humphreys K, , Strang J, et al. Drug policy and the public good. Oxford University Press, Oxford 2010
- Beccaria F, Sara R. Stakeholders’ role in contemporary “substitute drug” prescribing policies in Italy. Substance Use & Misuse 2013; 48: 943–953
- Bergmann M, Jahn T, Knobloch T, Krohn W, Pohl C, Schramm E. Methods for transdisciplinary research. Campus Verlag, Frankfurt 2012
- Dudley R. Ethanol, fruit ripening, and the historical origins of human alcoholism in primate frugivory. Integrative and Comparative Biology 2004; 44: 315–323
- Duke K, Herring R, Thickett A, Thom B. Substitution treatment in the era of ‘recovery’: An analysis of stakeholder roles and policy windows in Britain. Substance Use & Misuse 2013; 48: 966–976
- Eastwood N, Shiner M, Bear D. The numbers in black and white: Ethnic disparities in the policing and prosecution of drug offences in England and Wales. Release, London 2013
- Eisenbach-Stangl I. Deviance or innovation? Recent changes of drug substitution treatment policy in Austria. Substance Use & Misuse 2013; 48: 1010–1021
- Gable R. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction 2004; 94: 686–696
- Grayling AC. The God argument. Bloomsbury, London 2013
- Hagen EH, Sullivan RJ, Scmidt R, Morris G, Kempter R, Hammerstein P. Ecology and neurobiology of toxic avoidance and the paradox of drug reward. Neuroscience 2009; 160: 69–84
- Hall J, Giovannini E, Morrone A, Ranuzzi G. A framework to measure the progress of societies (OECD Statistics Directorate Working Paper No. 34). OECD, Paris 2010
- Hirsch Hadorn G, Hoffmann-Riem H, Biber-Klemm S, Grossenbacher-Mansuy W, Joye D, Pohl C, , Zemp E, et al. Handbook of transdisciplinary research. Springer, Berlin 2007
- Moskalewicz J, Welbel M. Walking through mud; history of the Polish methadone maintenance treatment from its stakeholders’ perspective. Substance Use & Misuse 2013; 48: 977–996
- National Confidential Enquiry into Patient Outcome and Death. Measuring the Units A review of patients who died with alcohol-related liver disease. National Confidential Enquiry into Patient Outcome and Death, London 2013
- Perälä R, Hellman M, Leppo A. Behind the scenes: The justifications for opioid maintenance treatment in Finland. Substance Use & Misuse 2013; 48: 954–965
- Strang J, Babor T, Caulkins J, Fischer B, Foxcroift D, Humphreys K. Drug policy and the public good: Evidence for effective interventions. Lancet 2012; 379: 71–83
- Sullivan RJ, Hagne EH, Hamerstein P. Revealing the paradox of drug reward in human evolution. Proceedings of the Royal Society B 2008; 275: 1231–1241
- WHO. Neuroscience of psychoactive substance use and dependence. World Health Organization, Geneva 2004